image:
Presenter: Alex Zhavoronkov, PhD, founder and CEO of Insilico Medicine
Session: Respiratory Innovation Summit
Date and time: Saturday, May 17, 11:30 a.m. – 12:00 p.m. PT
view more
Credit: Insilico Medicine
Cambridge, MA, May 7, 2025 — Insilico Medicine (“Insilico”), a clinical-stage biotechnology company driven by generative artificial intelligence (AI), today announced the company will present an oral presentation and three scientific posters at the American Thoracic Society (ATS) 2025 International Conference, taking place May 16-21, 2025, in San Francisco, California.
Led by Alex Zhavoronkov, Ph.D, founder and co-CEO of Insilico Medicine, Sujata Rao, M.D, Chief Medical Officer, Michelle Chen, Ph.D, Chief Business Officer, and Carol Satler, M.D, PhD, SVP of Clinical Development, the experienced Insilico team will be welcoming collaboration and clinical insight conversations at Booth #1464, Halls ABC Moscone Center.
All presentations will focus on exploring the potential of rentosertib (INS018_055), a novel TNIK inhibitor developed using Insilico’s generative AI approach, for the treatment of idiopathic pulmonary fibrosis (IPF). Previously, Insilico received encouraging results from a Phase IIa study of rentosertib, demonstrating its safety, tolerability, favorable pharmacokinetic profile, and preliminary clinical efficacy as measured by improvement in forced vital capacity (FVC) at 12 weeks. Notably, the study, for the first time, validated the biological mechanism of treating IPF by targeting TNIK—a novel target identified through generative AI—in a clinical setting, and presented the proof-of-concept validation of AI-driven drug discovery and development.
The following abstracts are posted on ATS 2025’s online itinerary planner for registered users:
Oral Presentation: Generative AI & The Future of Drug Development: A New Era of AI Designed IPF Drug Therapy
Presenter: Alex Zhavoronkov, PhD, founder and CEO of Insilico Medicine
Session: Respiratory Innovation Summit
Date and time: Saturday, May 17, 11:30 a.m. – 12:00 p.m. PT
Poster Presentation: Insilico Medicine: End-to-end generative AI-driven drug discovery and development
Session: Respiratory Innovation Summit
Date and time: Friday, May 16, 5:00 p.m. – 9:00 p.m. PT ; Saturday, May 17, 7:15 a.m. – 6:00 p.m. PT
Poster Presentation: An ASCENT to Week 8: INS018-055, A Novel Traf2- and NCK-interacting Kinase (TNIK) Inhibitor, Improves Lung Function in Patients With Idiopathic Pulmonary Fibrosis: Results From a Randomized, Double-blind, Placebo-controlled Phase 2a Study
Session A101: New Approaches To The Monitoring And Treatment of ILD
Poster: 8657
Date and time: Sunday, May 18, 2:15 p.m. – 4:15 p.m. PT
Poster Presentation: Biomarker Analysis Reveals Antifibrotic and Anti-inflammatory Signatures in Idiopathic Pulmonary Fibrosis Patients Treated With INS018_055, an AI-discovered TNIK Inhibitor, in a 12- week Phase 2a (Late Breaker)
Session C23: On The Horizon: Imaging And Molecular Biomarkers In Fibrotic ILD
Poster: 5115
Date and time: Tuesday, May 20, 9:15 a.m. – 11:15 a.m. PT
By integrating cutting-edge AI and automation technologies, Insilico Medicine has achieved significant efficiency gains compared to traditional drug discovery methods, which typically take 2.5–4 years. As announced in recent key timeline benchmarks for its 22 internal drug candidate programs from 2021 to 2024, Insilico has demonstrated remarkable performance, with an average timeline to DC of just 12–18 months, 60–200 molecules synthesized and tested per program, and a 100% success rate in advancing from DC to the IND-enabling stage.
In early 2024, Insilico published a Nature Biotechnology paper presenting the entire R&D journey from AI algorithms to Phase II clinical trials of ISM001-055, the company’s lead drug pipeline with AI-discovered target and AI-designed structure. Following that, Insilico has recently announced positive preliminary results from a Phase IIa trial (NCT05938920), where ISM001-055 showed favorable safety and tolerability across all dose levels, as well as dose-dependent response in forced vital capacity (FVC), after only 12 weeks of dosage.
About Insilico Medicine
Insilico Medicine, a global clinical stage biotechnology company powered by generative AI, is connecting biology, chemistry, medicine and science research using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. www.insilico.com
Media Contact
Joy Hu
InSilico Medicine
media@insilicomedicine.com
Office: 475-225-0843
Keywords
bu içeriği en az 2000 kelime olacak şekilde ve alt başlıklar ve madde içermiyecek şekilde ünlü bir science magazine için İngilizce olarak yeniden yaz. Teknik açıklamalar içersin ve viral olacak şekilde İngilizce yaz. Haber dışında başka bir şey içermesin. Haber içerisinde en az 12 paragraf ve her bir paragrafta da en az 50 kelime olsun. Cevapta sadece haber olsun. Ayrıca haberi yazdıktan sonra içerikten yararlanarak aşağıdaki başlıkların bilgisi var ise haberin altında doldur. Eğer yoksa bilgisi ilgili kısmı yazma.:
Subject of Research:
Article Title:
News Publication Date:
Web References:
References:
Image Credits:
Keywords
